MCT1 expression is independently related to shorter cancer-specific survival in clear cell renal cell carcinoma
Carregando...
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Autores
BONATELLI, Murilo
PINHEIRO, Celine
Citação
CARCINOGENESIS, v.42, n.12, p.1420-1427, 2021
Resumo
Clear cell renal cell carcinoma (ccRCC) has been considered a metabolic disease, with loss of von Hippel-Lindau (VHL) gene and consequent overexpression of hypoxia-inducible factor 1 alpha (HIF-1a), which is central for tumor development and progression. Among other effects, HIF-1a is involved in the metabolic reprogramming of cancer cells towards the Warburg effect involved in tumor cell proliferation, migration and survival. In this context, several proteins are expressed by cancer cells, including glucose and lactate transporters as well as different pH regulators. Among them, monocarboxylate transporters (MCTs) can be highlighted. Our aim is to comprehensively analyze the immunoexpression of MCT1, MCT2, MCT4, CD147, CD44, HIF-1 alpha, GLUT1 and CAIX in ccRCC surgical specimens correlating with classical prognostic factors and survival of patients with long follow-up. Surgical specimens from 207 patients with ccRCC who underwent radical or partial nephrectomy were used to build a tissue microarray. Immunostaining was categorized into absent/weak or moderate/strong and related to all classic ccRCC prognostic parameters. Kaplan-Meier curves were generated to assess overall and cancer-specific survival, and multivariate analysis was performed to identify independent prognostic factors of survival. Multivariate analysis showed that MCT1 together with tumor size and TNM staging, were independently related to cancerspecific survival. MCT1, CD147, CD44 and GLUT1 expression were significantly associated with poor prognostic factors. We show that MCT1 is an independent prognostic factor for cancer-specific survival in ccRCC justifying the use of new target therapies already being tested in clinical trials.
Palavras-chave
Referências
- Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703
- Almeida LMCA, 2017, HISTOL HISTOPATHOL, V32, P1029, DOI 10.14670/HH-11-863
- ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A
- Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074
- Boidot R, 2012, CANCER RES, V72, P939, DOI 10.1158/0008-5472.CAN-11-2474
- Camp RL, 2000, LAB INVEST, V80, P1943, DOI 10.1038/labinvest.3780204
- Cao YW, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2018.03.014
- Cichy J, 2003, J CELL BIOL, V161, P839, DOI 10.1083/jcb.200302098
- Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260
- Fang J, 2006, MOL PHARMACOL, V70, P2108, DOI 10.1124/mol.106.026245
- Finch NA, 2009, PROTEIN J, V28, P362, DOI 10.1007/s10930-009-9202-3
- Gallagher SM, 2007, CANCER RES, V67, P4182, DOI 10.1158/0008-5472.CAN-06-3184
- Gao HJ, 2015, J CANCER RES CLIN, V141, P1151, DOI 10.1007/s00432-014-1888-8
- Gordan JD, 2007, CURR OPIN GENET DEV, V17, P71, DOI 10.1016/j.gde.2006.12.006
- Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006
- Guile SD, 2006, BIOORG MED CHEM LETT, V16, P2260, DOI 10.1016/j.bmcl.2006.01.024
- Guo C, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0889-8
- Halestrap AP, 2012, IUBMB LIFE, V64, P1, DOI 10.1002/iub.573
- Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
- Izumi H, 2011, CANCER SCI, V102, P1007, DOI 10.1111/j.1349-7006.2011.01908.x
- Ke X, 2012, CARCINOGENESIS, V33, P1598, DOI 10.1093/carcin/bgs196
- Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061
- Kim Y, 2015, HUM PATHOL, V46, P104, DOI 10.1016/j.humpath.2014.09.013
- Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896
- Kondo K, 2002, GENE CHROMOSOME CANC, V34, P58, DOI 10.1002/gcc.10054
- Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108
- Linehan WM, 2013, SEMIN CANCER BIOL, V23, P46, DOI 10.1016/j.semcancer.2012.06.002
- Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4
- Marchiq I, 2015, CANCER RES, V75, P171, DOI 10.1158/0008-5472.CAN-14-2260
- Mathupala SP, 2004, NEUROSURGERY, V55, P1410, DOI 10.1227/01.NEU.0000143034.62913.59
- Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029
- Morais-Santos F, 2014, ENDOCR-RELAT CANCER, V21, P27, DOI 10.1530/ERC-13-0132
- Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184
- Orian-Rousseau V, 2010, EUR J CANCER, V46, P1271, DOI 10.1016/j.ejca.2010.02.024
- Ovens MJ, 2010, BIOCHEM J, V431, P217, DOI 10.1042/BJ20100890
- Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
- Pertega-Gomes N, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-312
- Pinheiro C, 2008, INT J GYNECOL PATHOL, V27, P568, DOI 10.1097/PGP.0b013e31817b5b40
- Pinheiro C, 2010, HISTOPATHOLOGY, V56, P860, DOI 10.1111/j.1365-2559.2010.03560.x
- Pinheiro C, 2009, EUR J CANCER, V45, P2418, DOI 10.1016/j.ejca.2009.06.018
- Pinheiro C, 2009, DIS MARKERS, V26, P97, DOI [10.3233/DMA-2009-0596, 10.1155/2009/169678]
- Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
- Puri S, 2020, EUR J MED CHEM, V199, DOI 10.1016/j.ejmech.2020.112393
- Rimpi S, 2007, BIOCHEM SOC T, V35, P305, DOI 10.1042/BST0350305
- Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397
- Slomiany MG, 2009, CANCER RES, V69, P1293, DOI 10.1158/0008-5472.CAN-08-2491
- Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843
- de Oliveira ATT, 2012, J BIOENERG BIOMEMBR, V44, P171, DOI 10.1007/s10863-012-9408-5
- Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015
- WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
- Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200
- Zhu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087904